E. Ohman J or Asset Management AB Has $4.73 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

E. Ohman J or Asset Management AB grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 13.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 11,740 shares of the pharmaceutical company’s stock after buying an additional 1,430 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Vertex Pharmaceuticals were worth $4,728,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Mutual Advisors LLC increased its position in Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 21 shares in the last quarter. Daymark Wealth Partners LLC increased its holdings in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after purchasing an additional 22 shares in the last quarter. Grove Bank & Trust raised its position in Vertex Pharmaceuticals by 5.7% in the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after purchasing an additional 22 shares during the last quarter. Outlook Wealth Advisors LLC lifted its holdings in Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock worth $415,000 after buying an additional 24 shares in the last quarter. Finally, Dunhill Financial LLC lifted its holdings in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $470.37 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business’s 50-day moving average price is $434.55 and its two-hundred day moving average price is $462.75. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.67 earnings per share. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VRTX. Scotiabank boosted their target price on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the stock a “sector perform” rating in a research report on Friday. Barclays cut their target price on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday. BMO Capital Markets cut their price objective on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a report on Friday, December 20th. Finally, Citigroup initiated coverage on shares of Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 target price for the company. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $502.58.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.